Cetuximab sarotalocan
As of the edition of 20 October 2026, Cetuximab sarotalocan is an antibody drug conjugate: marketed, first approved in 2020 (JP); acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Antibody drug conjugate
- Brand name
- Akalux
- First approved
- 25 September 2020 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Rakuten Medical
- Registered trials
- 3, 1 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Rakuten Medical | Applicant and Lead sponsor of trials | 2020 to now |